Frank S Czerwiec
Overview
Explore the profile of Frank S Czerwiec including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
2786
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Oberdhan D, Cole J, Krasa H, Cheng R, Czerwiec F, Hays R, et al.
Am J Kidney Dis
. 2017 Nov;
71(2):225-235.
PMID: 29150246
Background: The impact of autosomal dominant polycystic kidney disease (ADPKD) on health-related quality of life (HRQoL) is not well understood due to a lack of instruments specific to the condition....
12.
Perrone R, Mouksassi M, Romero K, Czerwiec F, Chapman A, Gitomer B, et al.
Kidney Int Rep
. 2017 Nov;
2(3):451-460.
PMID: 29142972
Introduction: Total kidney volume (TKV) is a promising imaging biomarker for tracking and predicting the natural history of patients with autosomal dominant polycystic kidney disease. Methods: A drug development tool...
13.
Perrone R, Mouksassi M, Romero K, Czerwiec F, Chapman A, Gitomer B, et al.
Kidney Int Rep
. 2017 Nov;
2(3):442-450.
PMID: 29142971
Introduction: Autosomal dominant polycystic kidney disease is the most common hereditary kidney disease. TKV is a promising imaging biomarker for tracking and predicting the natural history of autosomal dominant polycystic...
14.
Irazabal M, Blais J, Perrone R, Gansevoort R, Chapman A, Devuyst O, et al.
Kidney Int Rep
. 2017 Nov;
1(4):213-220.
PMID: 29142926
Introduction: Patients with slowly progressive autosomal dominant polycystic kidney disease (ADPKD) are unlikely to experience outcomes during randomized controlled trials (RCTs). An image classification of ADPKD into typical (diffuse cyst...
15.
Torres V, Chapman A, Devuyst O, Gansevoort R, Perrone R, Koch G, et al.
N Engl J Med
. 2017 Nov;
377(20):1930-1942.
PMID: 29105594
Background: In a previous trial involving patients with early autosomal dominant polycystic kidney disease (ADPKD; estimated creatinine clearance, ≥60 ml per minute), the vasopressin V-receptor antagonist tolvaptan slowed the growth...
16.
Cornec-Le Gall E, Blais J, Irazabal M, Devuyst O, Gansevoort R, Perrone R, et al.
Nephrol Dial Transplant
. 2017 Oct;
33(4):645-652.
PMID: 28992127
Background: The PROPKD score has been proposed to stratify the risk of progression to end-stage renal disease in autosomal dominant polycystic kidney disease (ADPKD) subjects. We aimed to assess its...
17.
Kline T, Korfiatis P, Edwards M, Blais J, Czerwiec F, Harris P, et al.
J Digit Imaging
. 2017 May;
30(4):442-448.
PMID: 28550374
Deep learning techniques are being rapidly applied to medical imaging tasks-from organ and lesion segmentation to tissue and tumor classification. These techniques are becoming the leading algorithmic approaches to solve...
18.
Torres V, Chapman A, Devuyst O, Gansevoort R, Perrone R, Dandurand A, et al.
Nephrol Dial Transplant
. 2017 Apr;
32(7):1262.
PMID: 28444221
No abstract available.
19.
Torres V, Chapman A, Devuyst O, Gansevoort R, Perrone R, Dandurand A, et al.
Nephrol Dial Transplant
. 2017 Apr;
33(3):477-489.
PMID: 28379536
Background: In TEMPO 3:4, the vasopressin V2 receptor antagonist tolvaptan slowed total kidney volume (TKV) growth and estimated glomerular filtration rate (eGFR) decline relative to placebo. Methods: TEMPO 4:4 was...
20.
Gralla R, Ahmad F, Blais J, Chiodo 3rd J, Zhou W, Glaser L, et al.
Cancer Med
. 2017 Mar;
6(4):723-729.
PMID: 28251822
Hyponatremia is a common electrolyte disorder in cancer patients and has been associated with poor prognosis. A frequent cause of cancer-related hyponatremia is the syndrome of inappropriate antidiuretic hormone (SIADH)....